What is Achieve Life Sciences's investing cash flow?

Achieve Life Sciences (ACHV) reported investing cash flow of $14.28M in Q1 2026.

How has Achieve Life Sciences's investing cash flow changed year-over-year?

Achieve Life Sciences's investing cash flow increased by 25.7% year-over-year, from $11.35M to $14.28M.

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

PfizerPFE

$785M-76.0%

Sionna Therapeutics, Inc. Common StockSION

$24.82M+118%

Philip Morris InternationalPM

-$3M+99.3%

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Achieve Life Sciences's investing cash flow?: Achieve Life Sciences (ACHV) reported investing cash flow of $14.28M in Q1 2026.
How has Achieve Life Sciences's investing cash flow changed year-over-year?: Achieve Life Sciences's investing cash flow increased by 25.7% year-over-year, from $11.35M to $14.28M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.